Literature DB >> 20055710

Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy.

Michael Bader1.   

Abstract

The renin-angiotensin-aldosterone system is one of the most important systems in cardiovascular control and in the pathogenesis of cardiovascular diseases. Therefore, it is already a very successful drug target for the therapy of these diseases. However, angiotensins are generated not only in the plasma but also locally in tissues from precursors and substrates either locally expressed or imported from the circulation. In most areas of the brain, only locally generated angiotensins can exert effects on their receptors owing to the blood-brain barrier. Other tissue renin-angiotensin-aldosterone systems are found in cardiovascular organs such as kidney, heart, and vessels and play important roles in the function of these organs and in the deleterious actions of hypertension and diabetes on these tissues. Novel components with mostly opposite actions to the classical renin-angiotensin-aldosterone systems have been described and need functional characterization to evaluate their suitability as novel drug targets.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20055710     DOI: 10.1146/annurev.pharmtox.010909.105610

Source DB:  PubMed          Journal:  Annu Rev Pharmacol Toxicol        ISSN: 0362-1642            Impact factor:   13.820


  99 in total

1.  The Renin-Angiotensin-Aldosterone System (RAAS) Is One of the Effectors by Which Vascular Endothelial Growth Factor (VEGF)/Anti-VEGF Controls the Endothelial Cell Barrier.

Authors:  Yueru Li; Zhonghao Yan; Komal Chaudhry; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2020-06-23       Impact factor: 4.307

Review 2.  The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes.

Authors:  Anand Vaidya; Jonathan S Williams
Journal:  Metabolism       Date:  2011-11-09       Impact factor: 8.694

Review 3.  Angiotensin II AT(1) receptor blockers ameliorate inflammatory stress: a beneficial effect for the treatment of brain disorders.

Authors:  Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2011-09-22       Impact factor: 5.046

Review 4.  Intracardiac intracellular angiotensin system in diabetes.

Authors:  Rajesh Kumar; Qian Chen Yong; Candice M Thomas; Kenneth M Baker
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

Review 5.  Blockade of brain angiotensin II AT1 receptors ameliorates stress, anxiety, brain inflammation and ischemia: Therapeutic implications.

Authors:  Juan M Saavedra; Enrique Sánchez-Lemus; Julius Benicky
Journal:  Psychoneuroendocrinology       Date:  2010-10-29       Impact factor: 4.905

6.  Increased urinary angiotensinogen is an effective marker of chronic renal impairment in very low birth weight children.

Authors:  Naoto Nishizaki; Daishi Hirano; Yuji Nishizaki; Shuichiro Fujinaga; Satoru Nagata; Yoshiyuki Ohtomo; Kazunari Kaneko; Toshiaki Shimizu
Journal:  Clin Exp Nephrol       Date:  2013-11-01       Impact factor: 2.801

Review 7.  The emerging role of aldosterone/mineralocorticoid receptors in the pathogenesis of erectile dysfunction.

Authors:  Fei Wu; Yun Lin; Qingyong Liu
Journal:  Endocrine       Date:  2018-05-02       Impact factor: 3.633

8.  CYCLOPS reveals human transcriptional rhythms in health and disease.

Authors:  Ron C Anafi; Lauren J Francey; John B Hogenesch; Junhyong Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2017-04-24       Impact factor: 11.205

9.  Elevated pressure causes endothelial dysfunction in mouse carotid arteries by increasing local angiotensin signaling.

Authors:  Yingzi Zhao; Sheila Flavahan; Susan W Leung; Aimin Xu; Paul M Vanhoutte; Nicholas A Flavahan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-05       Impact factor: 4.733

10.  Six commercially available angiotensin II AT1 receptor antibodies are non-specific.

Authors:  Julius Benicky; Roman Hafko; Enrique Sanchez-Lemus; Greti Aguilera; Juan M Saavedra
Journal:  Cell Mol Neurobiol       Date:  2012-07-28       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.